The management of acute chest pain remains a significant challenge in clinical practice, given its broad differential diagnosis and potential for severe outcomes. This article provides an overview of a comprehensive approach to evaluating and managing acute chest pain in the clinical setting.
Firstly, a thorough history and physical examination are crucial. The nature, location, duration, and radiation of pain, associated symptoms, and risk factors for cardiovascular disease should be elicited. Physical examination should focus on vital signs, cardiac and respiratory examinations, and signs of peripheral vascular disease.
Diagnostic testing should be guided by the pretest probability of disease. Electrocardiogram (ECG) and cardiac biomarkers are the first-line investigations. Further testing like stress testing, coronary computed tomography angiography (CCTA), or invasive coronary angiography may be indicated based on initial results and patient characteristics.
Risk stratification is essential to guide management. Multiple risk scores are available, including the HEART score and the GRACE score. These scores incorporate clinical, ECG, and biomarker findings to predict the risk of adverse outcomes and guide decision-making regarding hospitalization and further testing.
Management should be tailored to the underlying cause of chest pain and the patient's risk profile. This may range from reassurance and outpatient follow-up for low-risk patients to urgent revascularization for patients with acute coronary syndromes. All patients should receive education about warning signs and when to seek immediate medical attention.
In conclusion, a systematic approach to acute chest pain, including thorough initial evaluation, appropriate diagnostic testing, risk stratification, and patient-centered management, can help clinicians navigate this complex clinical scenario. Ongoing research and evolving guidelines will continue to refine our approach to this common, yet challenging, clinical problem.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation